Changes in indinavir exposure over time: A case study in six HIV-1-infected children

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 4, 2003, Pages 727-730

  Fraaij, P L A ^a   Bergshoeff, A S ^b   van Rossum, A M C ^a   Hartwig, N G ^a   Burger, D M ^b   de Groot, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Development; Indinavir; Paediatric HIV AIDS; Pharmacokinetic analysis; Pharmacokinetics; Protease inhibitors

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FLUCONAZOLE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SIZE; CASE STUDY; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GEOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PATIENT SELECTION; SIDE EFFECT; STANDARD; STEADY STATE; TIME; TREATMENT FAILURE; VIRUS LOAD;

ADOLESCENT; AREA UNDER CURVE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; INFANT; MALE; TIME FACTORS;

EID: 0141928518     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg391     Document Type: Article

References (13)

1. de Martino, M., Tovo, P. A., Balducci, M. et al. (2000). Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. Journal of the American Medical Association 284, 190-7.
2. Burger, D. M., van Rossum, A. M., Hugen, P. W. et al. (2001). Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrobial Agents and Chemotherapy 45, 701-5.
3. Burger, D. M., Hoetelmans, R. M., Hugen, P. W. et al. (1998). Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 3, 215-20.
4. Stein, D. S., Fish, D. G., Bilello, J. A. et al. (1996). A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10, 485-92.
5. van Rossum, A. M., Geelen, S. P., Hartwig, N. G. et al. (2002). Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clinical Infectious Diseases 34, 1008-16.
6. Gisolf, E. H., van Heeswijk, R. P., Hoetelmans, R. W. et al. (2002). Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 14, 801-5.
7. Huang, L., Wring, S. A., Woolley, J. L. et al. (2001). Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metabolism and Disposition 29, 754-60.
8. King, J. R., Kimberlin, D. W., Aldrovandi, G. M. et al. (2002). Antiretroviral pharmacokinetics in the paediatric population: a review. Clinical Pharmacokinetics 41, 1115-33.
9. Burger, D. M., de Graaff, M., Wuis, E. W. et al. (1997). Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatogaphy B, Biomedical Sciences and Applications 703, 235-41.
10. Hugen, P. W., Verweij-van Wissen, C. P., Burger, D. M. et al. (1999). Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatogaphy B, Biomedical Sciences and Applications 727, 139-49.
11. Gibaldi, M. (1991). Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics, 4th edn (Gibaldi, M., Ed.), pp. 14-23. Lea & Febiger, Philadelphia, PA, USA.
12. Burger, D. M. (2003). Drug interactions. [Online.] http://www.hivp-harmacology.com (8 April 2003, date last accessed).
13. van Rossum, A. M., Bergshoeff, A. S., Fraaij, P. L. et al. (2002). Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 21, 743-7.